drugset / Trial / NCT00406796
Lucentis for Central Retinal Vein Occlusion (CRVO)
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to determine whether ranibizumab will be effective in reducing if not eliminating the macular edema associated with the disease, central retinal vein occlusion (CRVO).
Timeline
- Start
- 2006-01
- Primary completion
- 2008-09
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ranibizumab | Monoclonal antibody | 0.3 mg | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |